Expanded Access to RXDX-105 for Cancers With RET Alterations

Roche

Status

Conditions: Cancers With RET Alterations

Treatments: Drug: RXDX-105

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03052569

RXDX-105 - EAP

Details and patient eligibility

About

Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of advanced cancer with RET alterations
• Unable to participate in an ongoing RXDX-105 clinical trial
• Willing and able to provide written, signed informed consent
• Medically suitable for treatment with RXDX-105

Exclusion criteria

• Prior treatment with a TKI that has activity against RET alterations
• Currently enrolled in an ongoing clinical study with any other investigational agent